MGNX MacroGenics Inc: רווח למניה ב-12 החודשים האחרונים

MacroGenics Corp (MGNX) - לוגו תאגידי

MacroGenics, Inc. (MGNX) is recognized for developing targeted antibodies that restore hope for oncology patients. However, the business faces risks of disrupted logistics chains and challenges in patent protection amid geopolitical pressure. Brand stability is confirmed by the trust of the global medical community. The market dynamics of the securities, with an EPS of 30.70, are presented below.

רווח נקי למניה (EPS TTM) MacroGenics Corp (MGNX): לתקופה 11.02.2024 - 15.11.2026

MGNX (macrogenics.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
הערכת שווי פונדמנטלית של החברה:MGNX - MacroGenics
דוגמת מוצר של MacroGenics, Inc.

MacroGenics, Inc. (MGNX) is developing an immuno-oncology portfolio based on the DART and TRIDENT platforms, mitigating clinical-stage risks through strategic partnerships. By analyzing this annual EPS TTM chart, an investor assesses the rate of change in earnings per share over the last twelve months, allowing for a comparison of real business efficiency against market capitalization and the determination of the company's fundamental stability during periods of price consolidation.